- Sofosbuvir/velpatasvir (SOF/VEL, Epclusa) and ledipasvir/sofosbuvir (LDV/SOF; Harvoni) achieved high HCV clearance rates in a pangenotypic real-world population.
Why this matters
- Rates of sustained virologic response at 12 weeks posttherapy (SVR12) were high regardless of treatment history or cirrhosis status.
- German study of 364 patients (median age, 50-56 years) with HCV genotypes (GT) 1-6.
- Regimens included:
- 12 weeks of SOF/VEL (n=80; 63.8% GT3, 21.2% cirrhotic, 87.5% treatment-naive).
- 12 weeks of SOF/VEL + ribavirin (n=35; 97.1% GT3, 94.3% cirrhotic, 74.3% treatment-naive).
- 8 weeks of LDV/SOF (n=129; 98.5% GT1, 0% cirrhotic, 97.7% treatment-naive).
- 12 or 24 weeks of LDV/SOF±ribavirin (n=120; 72.5% GT1, 46.7% cirrhotic, 63.3% treatment-experienced).
- Funding: Gilead Sciences, Inc.
- 99.1% SVR12 with 12 weeks of SOF/VEL±ribavirin for GT1-6.
- 99.2% SVR12 with 8 weeks of LDV/SOF, 93.0% with 12 or 24 weeks of LDV/SOF±ribavirin.
- Treatment-naive, noncirrhotic GT1: ≥99% SVR12 across SOF/VEL or LDV/SOF regimens.
- GT3 with cirrhosis: 100% SVR12 with SOF/VEL±ribavirin.
- 9 of 10 patients who had previously failed direct-acting antivirals (DAAs) achieved SVR12.
- All 20 HIV-coinfected patients achieved SVR12.
- Grade 3/4 adverse events were uncommon (SOF/VEL,
- Retrospective, monocentric, observational design.
- Small subgroup sample sizes.